Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden
- 1 April 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 15 (4) , 349-356
- https://doi.org/10.1097/00004872-199715040-00005
Abstract
To investigate components of the haemostatic and fibrinolytic system in borderline hypertensives and hypertensives, drug-treated or not, from a defined population. A randomly selected sample of the population of northern Sweden, 1558 subjects aged 25–64 years, was studied. Eight per cent of them were being treated with antihypertensive drugs (trHT). Remaining subjects were classified according to their mean diastolic blood pressure (DBP). Normotension, DBP Mean age increased from the normotensive group through the bHT and uHT groups to the trHT group, members of which were the oldest. Age-adjusted values for the body mass index, waist: hip ratio, serum triglyceride and Phadeseph plasma insulin levels increased with each level of hypertension. Plasma fibrinogen levels and plasminogen activator inhibitor type 1 activity (in men) increased stepwise from normotensives through bHT and uHT to the highest values found in the trHT group. The tissue plasminogen activator (tPA) activity in men declined strongly across the groups, trHT having the lowest fibrinolytic activity (P P Hypertension is associated with multiple metabolic and fibrinolytic disturbances that are accentuated in drug-treated hypertensives and already discernible in subjects with borderline hypertension. Decreased fibrinolysis is associated with, and possibly secondary to, metabolic disturbances linked to the insulin-resistance syndrome. The independent increase in tPA antigen in hypertensive men might indicate an endothelial dysfunction.Keywords
This publication has 37 references indexed in Scilit:
- Vascular Tissue Plasminogen Activator and the Development of Coronary Artery Disease in Heart-Transplant RecipientsNew England Journal of Medicine, 1995
- Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina PectorisNew England Journal of Medicine, 1995
- Insulin resistance, compensatory hyperinsulinaemia, and coronary heart diseaseDiabetologia, 1994
- Prospective study of endogenous tissue plasminogen activator and risk of strokeThe Lancet, 1994
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.Heart, 1991
- Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular diseaseJournal of Internal Medicine, 1990
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985